Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_assertion type Assertion NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_head.
- NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_assertion description "[Eight patients, five with pituitary carcinomas (three prolactin (PRL) and two ACTH) and three with aggressive pituitary tumors (one PRL and two ACTH), all treated with temozolomide administered orally for four to 24 cycles, were included in our French multicenter study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_provenance.
- NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_assertion evidence source_evidence_literature NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_provenance.
- NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_assertion SIO_000772 20660056 NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_provenance.
- NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_assertion wasDerivedFrom befree-2016 NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_provenance.
- NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_assertion wasGeneratedBy ECO_0000203 NP828307.RATDsYAlqMBrYY5EXp5hVrqK5NJAsmxRFTvydWSlki4sE130_provenance.